GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Artelo Biosciences Inc (NAS:ARTLW) » Definitions » Operating Cash Flow per Share

Artelo Biosciences (Artelo Biosciences) Operating Cash Flow per Share : $0.00 (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Artelo Biosciences Operating Cash Flow per Share?

Artelo Biosciences's operating cash flow per share for the three months ended in Mar. 2024 was $0.00. Artelo Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 46.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Artelo Biosciences's Operating Cash Flow per Share or its related term are showing as below:

ARTLW' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -342.2   Med: -72.7   Max: 47.3
Current: 46

During the past 10 years, Artelo Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 47.30% per year. The lowest was -342.20% per year. And the median was -72.70% per year.

ARTLW's 3-Year OCF Growth Rate is ranked better than
89.62% of 1233 companies
in the Biotechnology industry
Industry Median: 3.5 vs ARTLW: 46.00

Artelo Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Artelo Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Artelo Biosciences Operating Cash Flow per Share Chart

Artelo Biosciences Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Artelo Biosciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Artelo Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Artelo Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Artelo Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Artelo Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Artelo Biosciences's Price-to-Operating-Cash-Flow falls into.



Artelo Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Artelo Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=-8.207/0
=

Artelo Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Mar. 2024 )=Cash Flow from Operations (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=-2.942/0
=

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Artelo Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Artelo Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Artelo Biosciences (Artelo Biosciences) Business Description

Traded in Other Exchanges
Address
505 Lomas Santa Fe, Suite 160, Solana Beach, CA, USA, 92075
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing and commercializing treatments that control endocannabinoid system. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.

Artelo Biosciences (Artelo Biosciences) Headlines

From GuruFocus